Exciting happenings in retina research and care

In this video with Ophthalmology 360, Lexitas Chief Medical Officer, David Tanzer, MD, ABO, shares his expert insights on the latest retina research innovations, including the diverse landscape of gene therapies. He highlights several key players in the retinal gene therapy space, such as Ocugen, ikarovec, Adverum Biotechnologies, and 4D Molecular Therapeutics.

About David Tanzer, MD, ABO
David J. Tanzer, MD, ABO, is a board-certified, fellowship-trained ophthalmologist and the Chief Medical Officer at Lexitas Pharma Services. With over 25 years of experience across clinical practice, surgery, research, product development, and executive leadership, Dr. Tanzer has served in diverse roles with the U.S. Navy, private practice, Abbott Medical Optics, Johnson & Johnson Vision, Novartis Pharmaceuticals, OcuTerra Therapeutics, and now Lexitas. His expertise spans R&D, Medical Affairs, Safety, Commercialization, Compliance, and Quality Assurance within the healthcare space. Known for creating lasting organizational value through field credibility and strategic leadership, Dr. Tanzer has successfully led initiatives supporting product growth, patient safety, and global medical affairs excellence. His deep experience in clinical research includes all study phases, trial design and management, and scientific strategy—driving innovation for patients with ocular diseases.

Our Visionary Insights newsletter is published once a month and has thousands of subscribers. To stay in touch, subscribe today.